F ibrinolytic therapy has a weight-based dose of 0.9 mg/kg with a maximum dose limit of 90 mg according to the European licensing criteria for the application of alteplase for ischemic stroke in the 3-hour timeframe. Consequently, patients Ͼ100 kg body weight receive lower doses of alteplase per kilogram body weight compared with those Յ100 kg. However, overweight and obesity have been independently associated with the risk for ischemic stroke and their incidence is increasing in industrialized countries. [1] [2] [3] [4] Hence, the percentage of patients exceeding 100 kg is expected to rise. So far, there are only limited data available on the success of recanalization therapies in patients Ͼ100 kg, 5, 6 and it is unclear whether the lower dose per kilogram will result in less effective recanalization and poorer outcome in these patients.
Based on the patients registered within the Safe Implementation of Treatment in Stroke (SITS) International Stroke Thrombolysis Register (ISTR; https://sitsinternational.org), we investigated the hypothesis that the maximal alteplase dose of 90 mg may not be sufficient for people Ͼ100 kg as measured by major neurological improvement after thrombolysis and/or worse functional outcome.
Methods

Study Population and Design
The SITS database is a worldwide prospective, open, multinational, multicenter audit of thrombolysis. Details of data collection and management have been published previously. 7, 8 Data sets comprise information on baseline and demographic characteristics, including body weight, risk factors and medication history, baseline and follow-up stroke severity measured by National Institutes of Health Stroke Scale (NIHSS), baseline and follow-up (at 22 to 36 hours) imaging data, and information on functional outcome as assessed by modified Rankin Scale (mRS) at 3 months. The current analysis is based on patients undergoing thrombolysis for acute ischemic stroke and recorded within the SITS-ISTR registry. Recruitment of patients opened on December 25, 2002; the cutoff for the current analysis was November 2, 2009.
Outcome Measures
Outcome measures included major neurological improvement, incidence of symptomatic intracerebral hemorrhage (SICH), and functional outcome and mortality at 3 months.
Major neurological improvement (MNI) was used to estimate recanalization success and defined as improvement of Ն8 points on the NIHSS or a NIHSS of 0 at either (1) 2 hours; or (2) 24 hours after treatment. 5, 9 Incidence of SICH was assessed according to the SITS Monitoring Study (SITS MOST) criteria 7 (local or remote parenchymal hemorrhage Type 2 on the 22 to 36 hours post-treatment imaging scan combined with a neurological deterioration of Ն4 points compared with baseline NIHSS or the lowest NIHSS value between baseline and 24 hours) and the European-Australasian Acute Stroke Study (ECASS) II definition (any hemorrhage with neurological deterioration, as indicated by an NIHSS score Ն4 than the value at baseline or the lowest value within 7 days, or any hemorrhage leading to death). 10 mRS at 3 months was dichotomized into 0 to 2 versus 3 to 6 for independence and 0 to 1 versus 2 to 6 for excellent recovery.
Statistical Analysis
For comparison between patients Ͼ100 kg versus Յ100 kg, Pearson 2 and Mann-Whitney U tests were used where appropriate. For categorical variables, percentage proportions were calculated by dividing the number of events by the total number of patients, excluding missing or unknown cases. ORs for the different outcome parameters were calculated by comparing patients weighing Ͼ100 kg compared with those Յ100 kg. Adjusted ORs were calculated to account for substantial baseline differences between the 2 groups using logistic regression analysis. All variables that were significant (PϽ0.05) in univariate analysis as shown in Table 1 were included in the multivariable model. All statistical analyses were performed using the STATISTICA software (Version 8.0).
Results
Between December 2002 and November 2009, 28 136 patients were registered in SITS-ISTR and information on body weight was available for 27 910 (99.2%) patients. Of these, 14.6% (nϭ4100) had measured and 84.6% (nϭ23 810) had estimated weight. A total of 1190 (4.2%) patients were Ͼ100 kg (median, 110 kg; interquartile range, 13). The median weight of patients Յ100 kg was 75 kg (interquartile range, 18). Figure 1 shows the distribution of body weight in the SITS population.
Baseline Characteristics
Baseline characteristics of patients Ͼ100 kg as compared with those Յ100 kg are shown in Table 1 Overall, stroke etiology was similar for patients with Ͼ100 and Յ100 kg (Pϭ0.16 for the overall group). However, lacunar stroke slightly more often occurred in Ͼ100-kg group than Յ100 kg (11% versus 9%, Pϭ0.02).
The median alteplase dose for those Ͼ100 kg was 0.82 mg/kg as compared with 0.90 mg/kg for patients Յ100 kg (PϽ0.001). Onset-to-treatment time did not differ significantly between groups (median, 145 minutes for both groups).
Neurological Improvement After Thrombolysis
At 2 hours, MNI had occurred in 12.4% of patients Ͼ100 kg and in 14.0% of those Յ100 kg (OR, 0.86; 95% CI, 0.72 to 1.04; Pϭ0.11; Table 2 ). At 24 hours, MNI had occurred in 27.7% in both groups (OR, 1.00; 95% CI, 0.87 to 1.15; Pϭ0.99). *ORs were calculated by comparing patients weighing Ͼ100 kg compared with those Յ100 kg. †Adjusted for variables which were statistically significant (PϽ0.05) in the univariate analysis: age, sex, history of hypertension, diabetes mellitus, hyperlipidemia, smoking, stroke subtypes (lacunar versus other), baseline NIHSS, baseline blood glucose, blood pressure, and alteplase dose (mg/kg).
Analogously, median improvement on the NIHSS score from baseline to follow-up was similar in both groups: at 2 hours, both groups had improved by 2 points (interquartile range, 4; Pϭ0.12); at 24 hours, improvement of NIHSS was 3 points in both groups (interquartile range, 7; Pϭ0. 19 ).
Incidence of SICH
SICH per SITS MOST definition significantly more often occurred in patients Ͼ100 kg: 30 (2.6%) as compared with 454 (1.7%) of patients Յ100 kg (OR, 1.50; 95% CI, 1.03 to 2.18; Pϭ0.03). In contrast, SICH as per ECASS II definition occurred in 67 (5.9%) of patients Ͼ100 kg and in 1396 (5.5%) in the group Յ100 kg (OR, 1.08; 95% CI, 0.84 to 1.39; Pϭ0.55; Table 2 ). Figure 2 shows the mRS scores at 3 months. The unadjusted proportions of patients within each mRS score at 3 months were comparable in both group of patients but slightly better in the Ͼ100-kg than in the Յ100-kg group.
Functional Outcome and Mortality
At 3 months, 413 (42.3%) of patients Ͼ100 kg had made an excellent recovery (mRS, 0 to 1) as compared with 8416 (37.9%) of those Յ100 kg (OR, 1.20; 95% CI, 1.06 to 1.37; Pϭ0.005; Pϭ0.54). The leading cause of death was ischemic infarction in both groups. Equal proportions of patients in both groups had died because of hemorrhages, the combination of hemorrhage and cerebral ischemia, myocardial infarction, other vascular events, pulmonary embolism, or pneumonia.
Multivariable Analysis
The adjusted OR for MNI at 24 hours for patients Ͼ100 kg as compared with those Յ100 kg was 1.12 (95% CI, 0.97 to 1.30; Pϭ0.13; Table 2 ). After adjustment for baseline imbalances, there were no significant differences between the groups with respect to functional outcome at 3 months: the adjusted OR for independence was 0.99 (95% CI, 0.84 to 1.17; Pϭ0.93) and 1.01 (95% CI, 0.87 to 1.18; Pϭ0.87) for excellent recovery. However, despite the absolute lower mortality of patients Ͼ100 kg, adjusted ORs for mortality were significantly increased for those Ͼ100 kg (OR, 1.37; 95% CI, 1.08 to 1.74; Pϭ0.01).
The 
Discussion
In the present study, we have analyzed the so far the largest cohort (nϭ1190) of patients with ischemic stroke weighing Ͼ100 kg who were treated with intravenous thrombolysis. One previous small study including only 20 patients has shown a nonsignificant trend for an association between lower doses of recombinant tissue plasminogen activator and unfavorable 3-month outcomes. 6 In our study, we found that although patients Ͼ100 kg received a lower per-kilogram alteplase dose, the major neurological improvement at 2 and 24 hours is equal compared with patients Յ100 kg. Furthermore, there was no significant difference in functional outcome at 3 months between the Ͼ100-kg and Յ100-kg groups. However, we found a significantly increased rate of SICH according to the SITS MOST definition but not according to the ECASS II definition in patients Ͼ100 kg. Although there was no significant difference in the univariate mortality rates between the groups, surprisingly, the adjusted OR for mortality was significantly higher in the Ͼ100-kg group than the Յ100-kg group.
Solid evidence from transcranial Doppler studies and a study based on SITS data supports the close association between successful recanalization and MNI. [11] [12] [13] [14] The threshold of Ն8-points improvement on the NIHSS score was chosen in accordance with the literature, suggesting that lower thresholds may be too insensitive to the effects of alteplase. 5, 15, 16 Reanalyzing data from the National Institute of Neurological Disorders and Stroke (NINDS) trial, Brown and colleagues investigated predictors for MNI within 24 hours, including weight Ͼ100 kg among other variables. Seven percent (nϭ27) of the patients were weighing Ͼ100 kg compared with 4.3% (nϭ1190) in our study. Comparable to our data, the overall percentage of MNI was 32.5%, and MNI was found to be predictive for favorable functional outcome at 3 months. In this previous study, only age and stroke onset-to-treatment time were independently associated with MNI. Weight Ͼ100 kg did not exert a significant negative effect on MNI. This result was confirmed in our current study.
However, another reanalysis of the NINDS data including 20 recombinant tissue plasminogen activator (rtPA)-treated patients Ͼ100 kg reported a nonsignificant trend for an association between lower doses of rtPA and unfavorable 3-month outcomes. Furthermore, weight Ͼ100 kg was a predictor of poor outcome and neurological deterioration after rtPA treatment. 6 In contrast, including a by far larger population, we did not find a significant difference in odds for favorable functional outcome at 3 months between the 2 groups after adjustment for baseline imbalances. This finding again points toward sufficient efficacy of the maximum dose of 90 mg rtPA in patients Ͼ100 kg. The unadjusted analysis surprisingly showed a higher proportion of patients Ͼ100 kg achieving a favorable functional outcome compared with patients Յ100 kg. This finding most likely could be attributed to the fact that patients Ͼ100 kg were 8 years younger and had 2 points less severe strokes as measured by NIHSS score, age, and stroke severity being among the strongest predictors of outcome after ischemic stroke.
Interestingly, at the same time, the incidence of SICH per SITS MOST definition was significantly higher in patients Ͼ100 kg despite the significantly lower alteplase dose, the younger age, and less severe stroke. ORs for SICH per SITS definition remained significantly higher after adjustment for baseline imbalances. This finding is in line with a recently published analysis of the SITS MOST cohort including 6483 patients, identifying body weight as an independent predictor of SICH per SITS MOST definition (by 1 SD of 13.9; OR, 1.32; 95% CI, 1.09 to 1.60). 17 In the same analysis, it was observed that a lower per-kilogram alteplase dose was associated with higher mortality, 17 which was also confirmed in the current analysis. Although the point estimate for mortality at 3 months was lower in patients Ͼ100 kg than in patients Յ100 kg in the unadjusted analysis, there was a significantly increased odds of mortality for those weighing Ͼ100 kg in the multivariable analysis. Although the causes for this increase in mortality remain unclear, it is unlikely that lower per-kilogram dose causes higher mortality in the Ͼ100-kg than the Յ100-kg group.
Considering earlier studies using higher doses of rtPA 18, 19 or dose escalation studies of the newer generation thrombolytic agents, 20, 21 the comparable efficacy of thrombolytic therapy in terms of MNI, the equal odds for favorable functional outcome, and finally the increase in odds for SICH even under a lower per kilogram for patients Ͼ100 kg, the current study in summary confirmed the upper dose limit in clinical practice based on a large population.
Limitations of SITS data have been intensively discussed previously. 8, 17 A particular limitation of our current analysis is that most of the data on body weight were based on estimated weight, including weight indicated by the patients or the family or the attending physician. Only 14.5% of the patients had measured weight. Although according to previous studies, the patients' own estimations seem to be accurate with reported differences of approximately 2.7 kg, 22 physicians' estimations frequently seem to be more unreliable. 23 This represents a possible source of bias in the current study.
Conclusions
The lower per-kilogram body weight alteplase dose in patients Ͼ100 kg did not result in less successful thrombolysis compared with patients Յ100 kg as assessed by MNI, a surrogate marker of recanalization. Likewise, functional outcome did not differ between the groups after adjustment for baseline variables. Considering these findings and the higher incidence of SICH in patients Ͼ100 kg, our results support the current practice of the upper dose limit for rtPA.
